MX349754B - Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia. - Google Patents

Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia.

Info

Publication number
MX349754B
MX349754B MX2013014978A MX2013014978A MX349754B MX 349754 B MX349754 B MX 349754B MX 2013014978 A MX2013014978 A MX 2013014978A MX 2013014978 A MX2013014978 A MX 2013014978A MX 349754 B MX349754 B MX 349754B
Authority
MX
Mexico
Prior art keywords
indan
piperazine
trimethyl
chloro
phenyl
Prior art date
Application number
MX2013014978A
Other languages
English (en)
Other versions
MX2013014978A (es
Inventor
Holm Rene
Bruun Lone
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MX2013014978A publication Critical patent/MX2013014978A/es
Publication of MX349754B publication Critical patent/MX349754B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a la 4-((1R,3S)-6-cloro-3-fenil-i ndan-l-il) -1,2, 2-trimetil-piperazina y a sus sales con una actividad en los receptores de dopamina D1 y D2, así como también en el receptor 5HT2 de serotonina, para el tratamiento de enfermedades en el sistema nervioso central en un régimen de dosificación de una vez por semana.
MX2013014978A 2011-06-20 2012-06-20 Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia. MX349754B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161498653P 2011-06-20 2011-06-20
DKPA201100465 2011-06-20
PCT/EP2012/061779 WO2012175531A1 (en) 2011-06-20 2012-06-20 Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia

Publications (2)

Publication Number Publication Date
MX2013014978A MX2013014978A (es) 2014-04-10
MX349754B true MX349754B (es) 2017-08-11

Family

ID=58794324

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014978A MX349754B (es) 2011-06-20 2012-06-20 Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia.

Country Status (23)

Country Link
US (1) US9610287B2 (es)
EP (1) EP2720698B1 (es)
JP (1) JP6140151B2 (es)
KR (1) KR101900989B1 (es)
CN (1) CN103608015A (es)
AU (1) AU2012274150B2 (es)
BR (1) BR112013032178A2 (es)
CA (1) CA2838055C (es)
DK (1) DK2720698T3 (es)
ES (1) ES2694298T3 (es)
HR (1) HRP20181684T1 (es)
IL (1) IL230060A (es)
JO (1) JO3421B1 (es)
LT (1) LT2720698T (es)
MX (1) MX349754B (es)
PL (1) PL2720698T3 (es)
RS (1) RS57944B1 (es)
RU (1) RU2613177C2 (es)
SI (1) SI2720698T1 (es)
SM (1) SMT201800567T1 (es)
TW (1) TWI552751B (es)
WO (1) WO2012175531A1 (es)
ZA (1) ZA201309617B (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402400B2 (en) 2001-07-03 2008-07-22 Regents Of The University Of California Mammalian sweet taste receptors
AU780463B2 (en) 1999-11-17 2005-03-24 Mendel Biotechnology, Inc. Environmental stress tolerance genes
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
WO2002015675A1 (en) 2000-08-22 2002-02-28 Mendel Biotechnology, Inc. Genes for modifying plant traits iv
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
WO2003001876A2 (en) 2001-06-26 2003-01-09 Senomyx, Inc. T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
EP2436774A3 (en) 2002-08-01 2012-06-13 The Regents of The University of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
BR0314389A (pt) 2002-09-18 2005-07-12 Mendel Biotechnology Inc Polinucleotìdeos e polipeptìdeos em plantas
NZ572940A (en) 2003-05-30 2010-04-30 Agensys Inc Prostate stem cell antigen (PSCA) variants and subsequences thereof
EP2369347A1 (en) 2003-11-07 2011-09-28 Ciphergen Biosystems, Inc. Biomarkers for Alzheimer's disease
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
CN1964740A (zh) 2004-04-02 2007-05-16 加利福尼亚大学董事会 治疗和预防与αVβ5整联蛋白有关的疾病的方法和组合物
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
JP4651663B2 (ja) 2004-05-28 2011-03-16 アジェンシス，インコーポレイテッド Ｐｓｃａタンパク質に結合する抗体および関連分子
EP1766077B1 (en) 2004-06-21 2012-03-28 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
AU2006332045A1 (en) 2005-01-27 2007-08-16 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP2444099A1 (en) 2005-03-31 2012-04-25 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
HUE042197T2 (hu) 2005-07-19 2019-06-28 Stemgen S P A Tumor õssejtek tumorképzõ potenciáljának gátlása LIF segítségével
EP1937718B1 (en) 2005-10-20 2017-12-06 Senomyx, Inc. Chimeric human sweet-umami and umami-sweet taste receptors
CA2628238A1 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
DK2564864T3 (en) 2005-11-12 2015-04-07 Trustees Of The Leland Board Of FGF-2 related methods for the diagnosis and treatment of depression
CN101437933B (zh) 2005-12-28 2013-11-06 斯克里普斯研究所 作为药物靶标的天然反义和非编码的rna转录物
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US20090130108A1 (en) 2006-03-21 2009-05-21 The Regents Of The University Of California N-Cadherin and Ly6 E: Targets for Cancer Diagnosis and Therapy
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2423332A1 (en) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
NZ575090A (en) 2006-09-06 2012-02-24 Univ California Molecular diagnosis and classification of malignant melanoma using RGS1, ARPC2, FN1, SPP1 and WNT-2 polypeptide markers
EP2095100B1 (en) 2006-11-22 2016-09-21 President and Fellows of Harvard College Method of operating a nanowire field effect transistor sensor
AU2008287542C1 (en) 2007-06-01 2015-01-22 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
WO2009021708A2 (en) 2007-08-13 2009-02-19 Baxter International Inc. Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease
CN101828111B (zh) 2007-08-21 2014-07-23 塞诺米克斯公司 人t2r苦味受体及其用途
ES2908934T3 (es) 2007-10-04 2022-05-04 Zymogenetics Inc ZB7H6 miembro de la familia B7 y composiciones y métodos relacionados
EP2212693B1 (en) 2007-10-22 2015-04-22 The Regents of The University of California Biomarkers for prenatal diagnosis of congenital cytomegalovirus
EP2219671A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS
EP2955222B1 (en) 2008-03-17 2018-09-12 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
AU2009239491B2 (en) 2008-04-21 2014-07-17 Lawrence Livermore National Security, Llc Selective high-affinity polydentate ligands and methods of making such
JP2011529708A (ja) 2008-08-04 2011-12-15 ユニバーシティ オブ マイアミ 自然免疫応答の調節因子ｓｔｉｎｇ（インターフェロン遺伝子の刺激因子）
CN102224254A (zh) 2008-09-23 2011-10-19 哈佛大学校长及研究员协会 Sirt4及其用途
EP3260123A1 (en) 2008-11-06 2017-12-27 University of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
US8735082B2 (en) 2008-11-10 2014-05-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
ES2712074T3 (es) 2008-12-03 2019-05-09 Scripps Research Inst Cultivos de células madre
ES2645869T3 (es) 2008-12-17 2017-12-11 The Scripps Research Institute Generación y mantenimiento de células madre
KR20110140128A (ko) 2009-03-27 2011-12-30 고조 인더스트리즈, 인크 포자-표면 상호작용을 길항하는 화합물을 스크리닝 및 사용하기 위한 조성물 및 방법
JP5755647B2 (ja) 2009-07-24 2015-07-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア αｖβ５インテグリンに関連する疾患の処置および予防のための方法および組成物
DK3444613T3 (da) 2009-08-14 2021-06-21 Univ California Fremgangsmåder til diagnosticering og behandling af autisme
EP2467398B1 (en) 2009-08-20 2019-10-09 Poseida Therapeutics, Inc. Trpc4 inhibitors and uses thereof
WO2011038228A1 (en) 2009-09-24 2011-03-31 President And Fellows Of Harvard College Bent nanowires and related probing of species
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
US20130137584A1 (en) 2010-02-01 2013-05-30 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
US20120301904A1 (en) 2011-04-26 2012-11-29 Prosetta Antiviral, Inc Multiprotein assemblies
US9408832B2 (en) 2012-03-14 2016-08-09 University Of Central Florida Research Foundation, Inc. LIM kinasemodulating agents for neurofibromatoses therapy and methods for screening for same
CN104379563B (zh) 2012-04-10 2018-12-21 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
EP2841450A2 (en) 2012-04-24 2015-03-04 University of Miami Perforin 2 defense against invasive and multidrug resistant pathogens
WO2014018535A1 (en) 2012-07-25 2014-01-30 Salk Institute For Biological Studies Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
AU2013204200B2 (en) 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
DK2954323T3 (da) 2013-02-07 2020-07-20 Univ California Anvendelse af translationsprofilering til identifikation af målmolekyler til terapeutisk behandling
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
US10280169B2 (en) 2013-12-11 2019-05-07 Biogen Ma Inc. Biaryl bruton's tyrosine kinase inhibitors
WO2015089338A2 (en) 2013-12-11 2015-06-18 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
WO2015136509A2 (en) 2014-03-14 2015-09-17 Genesis Theranostix Korlatolt Felelossegu Tarsasag Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy
US10196701B2 (en) 2015-06-01 2019-02-05 The Penn State Research Foundation Hepatitis B virus capsid assembly
WO2016207313A1 (en) 2015-06-24 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for detecting protein-protein interactions
WO2018036503A1 (en) 2016-08-25 2018-03-01 The Chinese University Of Hong Kong Fecal bacterial markers for colorectal cancer
AU2017378487B2 (en) 2016-12-15 2022-03-31 The Regents Of The University Of California Compositions and methods for treating cancer
US11555031B2 (en) 2017-03-20 2023-01-17 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
AU2018248423A1 (en) 2017-04-04 2019-10-17 Loma Linda University Biologic for the treatment of cancer
US20210247386A1 (en) 2018-04-26 2021-08-12 Technion Research & Development Foundation Limited A device and method for determining cell indentation activity
ES3023937T3 (en) 2018-10-31 2025-06-03 The Westmead Institute For Medical Res Pharmaceutical compositions for use in treating an hbv or hdv infection
WO2020097261A1 (en) 2018-11-06 2020-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New compositions and methods for treating beta-globinopathies
EP4247427A4 (en) 2020-11-19 2025-04-09 The Chinese University of Hong Kong Assessing risk for colorectal adenoma recurrence by noninvasive means
WO2023081167A2 (en) 2021-11-02 2023-05-11 The Regents Of The University Of California P-selectin mutants and modulation of integrin-mediated signaling
US20250092106A1 (en) 2022-01-25 2025-03-20 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling
WO2024197185A1 (en) 2023-03-21 2024-09-26 The Broad Institute, Inc. Methods and compositions for dissecting organelle physiology

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK55192D0 (da) 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
NZ575575A (en) 2003-08-18 2010-04-30 Lundbeck & Co As H Succinate and malonate salt of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
NZ551340A (en) 2004-04-22 2010-10-29 Boehringer Ingelheim Int Pharmaceutical composition comprising flibanserin and a melanocortin agonist for the treatment of premenstrual disorder or sexual aversion disorder
MX362908B (es) 2005-07-18 2019-02-21 Univ Pennsylvania Implantes que contienen fármacos y métodos de uso de los mismos.
CN102065861B (zh) * 2008-05-07 2013-10-16 H.隆德贝克有限公司 反式-4-((1r，3s)-6-氯-3-苯基茚满-1-基)-1，2，2-三甲基哌嗪用于改善认知的用途
NZ590897A (en) * 2008-10-03 2012-07-27 Lundbeck & Co As H ORAL FORMULATION COMPRISING (4-((1R,3S)-6-chloro-3-phenylindan-l-yl)-1,2,2-trimethylpiperazine)
CN102596172A (zh) 2009-06-24 2012-07-18 Msd欧斯股份有限公司 含有阿塞那平的注射剂和使用其的治疗方法

Also Published As

Publication number Publication date
US9610287B2 (en) 2017-04-04
EP2720698A1 (en) 2014-04-23
TWI552751B (zh) 2016-10-11
LT2720698T (lt) 2018-11-12
RU2014101482A (ru) 2015-07-27
EP2720698B1 (en) 2018-10-03
US20140194409A1 (en) 2014-07-10
KR101900989B1 (ko) 2018-09-20
HRP20181684T1 (hr) 2018-12-14
BR112013032178A2 (pt) 2016-12-20
DK2720698T3 (en) 2018-11-26
ES2694298T3 (es) 2018-12-19
WO2012175531A1 (en) 2012-12-27
CN103608015A (zh) 2014-02-26
AU2012274150A1 (en) 2014-01-09
SMT201800567T1 (it) 2018-11-09
JP6140151B2 (ja) 2017-05-31
ZA201309617B (en) 2015-04-29
PL2720698T3 (pl) 2019-01-31
JP2014517050A (ja) 2014-07-17
AU2012274150B2 (en) 2016-10-06
SI2720698T1 (sl) 2018-12-31
CA2838055C (en) 2021-01-26
CA2838055A1 (en) 2012-12-27
RU2613177C2 (ru) 2017-03-15
RS57944B1 (sr) 2019-01-31
TW201306840A (zh) 2013-02-16
JO3421B1 (ar) 2019-10-20
MX2013014978A (es) 2014-04-10
KR20140033419A (ko) 2014-03-18
IL230060A (en) 2017-10-31

Similar Documents

Publication Publication Date Title
MX349754B (es) Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia.
MY174888A (en) Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
IN2014DN09434A (es)
MD4538B1 (ro) 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei
PH12014500355A1 (en) Lysophosphatidic acid receptor antagonists
PH12014501056A1 (en) New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
MX343620B (es) Forma polimorfica de clorhidrato de pridopidina.
EA201400569A1 (ru) Новые производные циклогексиламина, обладающие агонистической активностью по отношению к бета-2 адренергическому рецептору и антагонистической активностью по отношению к мускариновому рецептору м3
UA109260C2 (uk) Хромонові похідні, спосіб їх одержання та їх терапевтичні застосування
CL2013003042A1 (es) Compuestos derivados metilamina de biciclos sustituidos, moduladores de receptores de esfingosin-1- fosfato; composicion farmaceutica; y un metodo de tratamiento para tratar enfermedades oculares, degeneracion macular, retinopatia, entre otros
TN2015000271A1 (en) New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
GEP201606526B (en) 5-ht3 receptor antagonists
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX2014000855A (es) Moduladores receptores de glucagon de quinolinilo.
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
WO2012149481A8 (en) Novel peptide inhibitors of serotonin 5-ht2c receptor:pten interaction
TN2013000503A1 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
MY166773A (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
CY1120838T1 (el) Μεθοδος χορηγησης 4-((1r,3s)-6-xλωpo-3-φainyλo-inδan-1-yλo)-1,2,2-τριμεθυλο-πιπεραζινης και των αλατων αυτης στην αντιμετωπιση σχιζοφρενειας

Legal Events

Date Code Title Description
FG Grant or registration